News & Updates
Filter by Specialty:
![Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure](https://sitmspst.blob.core.windows.net/images/articles/initial-cpap-uptake-predictive-of-1-year-adherence-in-patients-with-osa-219849fd-9cbc-4272-904d-224de11377c5-square.jpg)
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
27 Oct 2021![Chronic constipation not a risk factor for later colorectal cancer](https://sitmspst.blob.core.windows.net/images/articles/fotolia97046192-2ffbbcba-10a3-40e9-a0fd-ed3821172d59-square.jpg)
Chronic constipation not a risk factor for later colorectal cancer
Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021![High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D](https://sitmspst.blob.core.windows.net/images/articles/high-dose-semaglutide-improves-glucose-metabolism-outcomes-in-overweightobese-patients-with-t2d-a1d371c3-67a5-46dc-bc71-d8a6acb136aa-square.jpg)
High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D
Treatment with a higher dose of semaglutide led to significantly improved glucose metabolism outcomes in patients with overweight/obesity and type 2 diabetes (T2D) compared with a lower dose of semaglutide or placebo, according to the STEP* 2 trial presented at EASD 2021.
High-dose semaglutide improves glucose metabolism outcomes in overweight/obese patients with T2D
27 Oct 2021![Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?](https://sitmspst.blob.core.windows.net/images/articles/durvalumab-tremelimumab-chemo-a-new-first-line-soc-for-mnsclc-f8acb41c-af30-4f09-95d1-317f935513a5-square.jpg)
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.